

# Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

## MES-SA/Dx5

RRID:CVCL\_2598

Type: Cell Line

### Proper Citation

RRID:CVCL\_2598

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2598](https://web.expasy.org/cellosaurus/CVCL_2598)

**Proper Citation:** RRID:CVCL\_2598

**Description:** Cell line MES-SA/Dx5 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Uterine corpus sarcoma

**Defining Citation:** [PMID:4028002](#), [PMID:15816562](#), [PMID:20215515](#), [PMID:22889595](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:28196595](#)

**Comments:** Population: Caucasian., Part of: MD Anderson Cell Lines Project.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MES-SA/Dx5

**Synonyms:** MES-SA/Dx-5, MES-SA-Dx5, MES-SA Dx5, MESSA/Dx5, MESSA-DX5, MESSA Dx5, MESSADX5, Dx5

**Cross References:** CLO:CLO\_0007678, CLO:CLO\_0037164, CLDB:cl3449, ArrayExpress:E-MTAB-38, ATCC:CRL-1977, BCRC:60331, BCRJ:0403, BioSample:SAMN03470985, BioSample:SAMN03471267, cancercellines:CVCL\_2598, Cell\_Model\_Passport:SIDM01225, ChEMBL-Cells:ChEMBL3308373, ChEMBL-Targets:ChEMBL613827, ECACC:95051031, GEO:GSM827348, GEO:GSM1676305, GEO:GSM1701640, IGRhCellID:MESSADX5, LINCS\_LDP:LCL-1510, Progenetix:CVCL\_2598, PubChem\_Cell\_line:CVCL\_2598, Wikidata:Q54905250

**ID:** CVCL\_2598

**Hierarchy:** cvcl\_1404

**Record Creation Time:** 20220427T220803+0000

**Record Last Update:** 20260913T004848+0000

---

## Ratings and Alerts

No rating or validation information has been found for MES-SA/Dx5.

**Warning:** Discontinued: ATCC; CRL-1977

Population: Caucasian., Part of: MD Anderson Cell Lines Project.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. Molecular oncology.

Gori A, et al. (2023) Investigation of Chemical Composition and Biological Activities of *Ajuga pyramidalis*-Isolation of Iridoids and Phenylethanoid Glycosides. Metabolites, 13(1).

Rozga P, et al. (2020) Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. International journal of cancer, 147(4), 1117.